<img src="http://www.33-trk-srv.com/82019.png" style="display:none;">

Tissue Dissociation Steps Video

 

FlowMetric Fast Facts

  • Over 100 clients ranging from large pharma, biotech, to the hospital setting
  • Ability to measure up to 16 parameters simultaneously
  • Expertise in multiple species & sample types
  • Multi-City site experience, domestic & international
  • Philadelphia Business Journal award for "Best CRO" in 2012

Why Choose FlowMetric

FlowMetric was established to deliver decision-enabling data on programs that matter the most to you. Partners choose us because of our expertize, our focus, our approach and results we have delivered.

Learn More

A Video From FlowMetric's CEO & Founder

 

Get Our Latest Whitepaper

Immuno-Oncology Research and Flow Cytometry

News from FlowMetric

  • Are Your Cells Feeling Ill? - Using Flow Cytometry to Measure Oxidative Stress View Post Summary

    Measuring oxidative stress has become an essential element in defining features of the immune response, and understanding how cells respond to infection, chronic disease and cancer. Quantifying oxidative stress is also critical to understanding how experimental treatments affect cells, and this information is critical to determining the risks and benefits of a potential new therapy. Oxidative stress can also serve a functional purpose. Phagocytic cells like neutrophils undergo a “respiratory burst” and produce reactive oxygen species (ROS) in order to destroy intracellular pathogens.

    Read the full article »
  • Detecting Minimal Residual Disease by Flow Cytometry View Post Summary

    Unlike solid tumors, blood cancers such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) may be monitored by measuring the presence and frequency of cancerous blood cells in the peripheral blood or bone marrow. Minimal residual disease (MRD) assessment uses different techniques to measure the presence of malignant cells, even at low frequency, and has been used as a key prognostic for guiding treatment decisions in pediatric and adult leukemia patients and assigning patients into different MRD-based risk groups. [1]

    Read the full article »
  • Mind the Mechanism - Using Flow Cytometry to Determine Mechanisms of Action for Therapeutic Antibodies View Post Summary

    Immunotherapy research is a rapidly expanding field in which dozens of monoclonal antibodies are being developed to treat cancer and autoimmune diseases. The mechanism of action (MOA) used by an antibody to mediate a therapeutic response must be defined in order for a candidate antibody to advance down the preclinical development pipeline. Defining the MOA is necessary to fulfilling regulatory requirements for antibodies used in clinical trials and also critical to understanding if the antibody may cause any detrimental side effects.

    Read the full article »